Transgene Biotek Cash Flow Statement

Financials in millions INR. Fiscal year is April - March.

Millions INR. Fiscal year is Apr - Mar.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '25 Mar 31, 2025	Mar '24 Mar 31, 2024	Mar '23 Mar 31, 2023	Mar '22 Mar 31, 2022	Mar '21 Mar 31, 2021
Net Income	-6.76	-6.56	-60.09	-104.02	-104.35
Depreciation & Amortization	0.93	0.92	49.5	99.24	99.08
Provision & Write-off of Bad Debts	-0.07	-	-	-	-
Other Operating Activities	0.68	-0.46	0.06	0.51	0.91
Change in Inventory	-0	-0	0.61	-0.74	0.18
Change in Accounts Payable	13.98	-0.26	0.26	-0.37	-1.4
Change in Other Net Operating Assets	3.21	6.4	9.66	6.35	5.7
Operating Cash Flow	11.96	0.05	0	0.98	0.13
Operating Cash Flow Growth	25895.65%	2200.00%	-99.80%	678.19%	-90.98%
Capital Expenditures	-17	-	-0.02	-	-0.27
Cash Acquisitions	-	-	-	-0.95	-
Other Investing Activities	-	-	-0.11	-0.02	-
Investing Cash Flow	-17	-	-0.12	-0.97	-0.27
Long-Term Debt Issued	60	-	-	-	-
Total Debt Issued	60	-	-	-	-
Long-Term Debt Repaid	-49.77	-	-	-	-
Net Debt Issued (Repaid)	10.23	-	-	-	-
Issuance of Common Stock	-	-	-	-	0
Other Financing Activities	-2.43	-	-	-	-
Financing Cash Flow	7.8	-	-	-	0
Miscellaneous Cash Flow Adjustments	-	-	0	-	-
Net Cash Flow	2.77	0.05	-0.12	0.01	-0.15
Free Cash Flow	-5.04	0.05	-0.01	0.98	-0.15
Free Cash Flow Margin	-193.21%	1.96%	-2.36%	112.81%	-8.74%
Free Cash Flow Per Share	-0.07	0.00	-	0.01	-0.00
Cash Interest Paid	2.43	-	-	-	-
Levered Free Cash Flow	-2.95	-5.77	10.63	-21.87	29.44
Unlevered Free Cash Flow	-1.43	-4.9	11.76	-20.44	31.13
Change in Working Capital	17.19	6.14	10.53	5.24	4.48

Source: S&P Global Market Intelligence. Standard template. Financial Sources.